MEMORANDUM OPINION AND ORDER
Is thеre a duty to warn the subject of radiation treatments when a physician in charge of a hospital research program created to investigate the risks of its previous radiation treatment policies uncovers in his research a strong connection between those treatments and certain sorts of tumors? Here the physician contends that he had no duty to warn because he was not the subject’s treating physician. I conclude that Illinois law does not support his argument and that he had a duty to warn.
I.
About 5,000 patients at Michael Reese Hospital and Medical Center (“Michael Reese”), located in.Chicago, Illinois, were treated with X-ray therapy for some benign conditions of the head and neck from 1930 to 1960. Among them was Joel Blaz, now a citizen of Florida, who received this treatment for infected tonsils and adenoids while a child in Illinois in 1947-48. He has suffered various tumors which he now attributes to this treatment. Blaz was diagnosed with a neural tumor in 1987.
In 1974, Michael Reese set up a Thyroid Follow-Up Projeсt (the “Program”) to gather data and conduct research among the people who had been subjected to the x-ray therapy. In 1975, the Program notified Blaz by mail that he was at increased risk of developing thyroid tumors because of the treatment. In 1976, someone associated with the Program gave him similar information by phone and invited him to return to Michael Reese for evaluation and treatment at his own expense, which he declined to do.
Dr. Arthur Schneider was put in charge of the Program in 1977. In 1979, Dr. Schnеider and Michael Reese submitted a research proposal to the National Institutes for Health (“NIH”) stating that a study based on the Program showed “strong evidence” of a connection between x-ray treatments of the sort administered to Blaz and various sorts of tumors, thyroid, neural, and other. In 1981, Blaz received but did not complete or return a questionnaire attached to a letter from Dr. Schneider in connection with the Program. The letter stated that the purpose of the questionnaire was to “invеstigate the long term health implications” of childhood radiation treatments and to “determine the possible associated risks.” It did not say anything about “strong evidence” of a connection between the treatments and any tumors.
In 1996, after develoрing neural tumors, Blaz sued Michael Reese’s successor, Galen Hospital, Illinois, and Dr. Schneider, alleging, among other things, that they failed to notify and warn him of their findings that he might be at greater risk of neural tumors in a way that might have permitted their earlier detectiоn and removal or other treatment. Much litigation ensued, including this motion to dismiss Dr. Schneider from the action, which I now consider. 1
*805 ii.
This is a diversity case, so I apply state substantive and federal procedural law.
Erie R. Co. v. Tompkins,
A federal court sitting in diversity must attempt to predict how the state supreme court would decide the issues presented here.
Dawn Equipment Co. v. Micro-Trak Sys., Inc.,
The question here is whether a physician who directed a hospital research project inquiring into the risks of treatments the hospital formerly administered has a duty to warn a patient whom he never treated of the risks attendant on those treatments. No Illinois cases speak directly to this question, but the general criteria for the existence of a legal duty established by the Illinois Supreme Court are: (1) “whether the harm reasonably was foreseeable,”
Kirk v. Michael Reese Hosp.
Under this framework, it is clear that a duty to warn exists. The harm alleged here, neural and other tumors, would here be reasonably foreseeable as a likely consequence of a failure to wаrn, and was in fact foreseen by Dr. Schneider. A reasonable physician, indeed any reasonable person, could foresee that if someone were warned of “strong evidence” of a connection between treatments to which he hаd been subjected and tumors, he would probably seek diagnosis or treatment and perhaps avoid these tumors, and if he were not warned he probably would not seek diagnosis or treatment, increasing the likelihood that he would suffer from such tumors. Other things being equal, therefore, a reasonable physician would warn the subject of the treatments.
Moreover, other things are indeed equal. The likelihood of injury is hard to calculate in this case, but even supposing that it was small, the burden on the defendant was negligible, since Dr. Schneider was already
*806
in communication with Mr. Blaz and might easily have informed him in the 1981 letter, if not sooner,, of the same things he had told the NIH. Moreover, placing the burden on the defendant rather than the plaintiff is the only decision that makes sensе, since Dr. Schneider was in a special position to acquire the information and had in fact done so, while Mr. Blaz was in no position to find out.
See Kokoyachuk,
As I have stated in a previous opinion, this case is analogous to
Mink v. Univ. of Chicago,
Dr. Schneider and Michael Reese argue to the contrary from the fact that Dr. Schneider, unlike the physicians involved in
Mink,
was never Mr. Blaz’s physician, so no physician-patient relationship with its attendant legal responsibilities ever existed between them. However, Dr. Schneider had the duty to warn in virtue of his role as the physician in charge of the hosрital’s Program. He was not Mr. Blaz’s treating physician, but he was the physician designated by Michael Reese to direct the Program which was responsible for researching the effects of the radiation treatment and communicating with the hospital’s former рatients in regard to those treatments. “A modern hospital ... is an amalgam of many individuals .... Moreover, it is clear that at times a hospital functions far beyond the narrow sphere of medical practice.”
Pitler v. Michael Reese Hosp.,
Dr. Schneider and Michael Reese object that he had no such duty because, since he was nоt the treating physician, he did not create the risk to which Mr. Blaz was exposed. This argument is not to the point. First, Dr. Schneider’s duty was complementary to the hospital’s duty to its patients, regardless of who treated them, to conform to the legal standard of rеasonable conduct in light of the apparent risk.
Magana v. Elie,
Second, I hold that Dr. Schneider’s position as the person in charge of the Program involved in researching the effects of the radiation treatments and contacting patients who had been subjected to them created the sort of “special relationship” the Illinois Supreme Court requires for a
*807
finding of duty in the absence of a physician-patient relationship.
Kirk,
In dеtermining whether a duty exists, the Illinois Supreme Court sensibly conducts a policy analysis rather than applying a cookie cutter. In
Kirk,
that Court rejected a “broad duty extended to the general public [which] would expand the physician’s duty of care to аn indeterminate class of potential plaintiffs.”
The only policy concern I can see here is that it might be thought to inhibit research into the effects of medical treatment if nontreating physicians in charge of such research programs are held to have a duty to warn the former patients of risks discovered in that research. But this does not strike me as a real worry. First, the duty would be discharged by a mere warning which, as explained, would here have been neither costly nor burdensome to give. The mоre costly and burdensome the warning would be to give, of course, the less likely there would be a finding of duty. Second, the medical researchers’ legitimate desire for professional prestige and honor due to new discoveries, see generally Robert K. Merton, The Sociology of Science (1973), would counteraсt any such inhibition; as of course would the concern for the well-being of its former patients which any self-respecting hospital would have.
Against this rather nebulous and unsubstantial worry I must balance the fact that a finding of no duty would allow physicians in charge of hospital research programs into the risks of treatment policies to exploit the results of that research for their professional advancement and curiosity without warning the patients of any risks connected with those treatments which their resеarch discovered, however little the cost of warning. I can see no social benefit in creating such a perverse incentive structure, particularly in view of the costs to the patients and society of preventable tumors and other illnеsses. Preventative care is not an overriding good, but it is a considerable one.
The long and short of it is that Dr. Schneider, in virtue of his position, was not entitled to use the information he had acquired about the risk to former patients for his own professional advancement without warning them of the risks which his own research had suggested that the hospital’s treatments had created for them. His motion to dismiss is therefore DENIED.
Notes
. Dr. Schneider presented this as a motion for summary judgment and then as a motion for clarification of my ruling on that motion. I decided to treat the motion as a motion to *805 dismiss for failure to state a claim, Rule 12(b)(6), or for judgment on the pleadings, Rule 12(c), and so analyze it here.
.
See United States v. Carroll Towing Co.,
